# Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)

> **NCT01724879** · PHASE2 · COMPLETED · sponsor: **Goethe University** · enrollment: 19 (actual)

## Conditions studied

- Philadelphia Positive Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Dasatinib

## Key facts

- **NCT ID:** NCT01724879
- **Lead sponsor:** Goethe University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2015-09
- **Final completion:** 2015-09
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2022-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01724879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01724879, "Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01724879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*